Bartosz Hudzik/LinkedIn
Feb 11, 2026, 16:08
Bartosz Hudzik: Clinical Trials to Watch in 2026 – A Cardiovascular Lens
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn:
“Clinical trials to watch in 2026 — a cardiovascular lens
Nature Medicine highlights 11 trials poised to shape medicine in 2026. In cardiology, two stand out:
- Ziltivekimab – targeting the IL-6 inflammatory pathway to reduce residual inflammatory risk in atherosclerosis and CKD, moving beyond lipid-only prevention.
- Pelacarsen – a first-in-class antisense therapy for lipoprotein(a), tackling one of the most important genetically driven and previously untreatable CV risk factors.
Both are Phase 3 programs with the potential to redefine precision prevention.
2026 may be the year cardiovascular medicine shifts from risk markers to causal, target-specific therapies.”

More posts featuring Bartosz Hudzik on Hemostasis Today.
-
Nov 20, 2026, 14:21Chris Oung: Postoperative VTE Risk and Timing Across Surgical Specialties
-
Nov 20, 2026, 14:17Melissa Pickett: HIT Detection Can Miss a Critical Platelet Decline
-
Nov 20, 2026, 14:02Hasan Burak İşleyen։ Thrombocytopenia and Mortality in Critically Ill Cancer Patients
-
Nov 20, 2026, 13:50Louise Maes: CONVINCE Trial Imaging Studies Reveal New Insights Into Carotid Plaque and Vascular Risk
-
Nov 20, 2026, 13:50Lara Kurdi: A Presentation of Triple-Positive Antiphospholipid Syndrome
-
Nov 20, 2026, 13:46Rahul Bohra: Beyond Platelet Counts – The Lived Experience of ITP
-
Nov 20, 2026, 13:34Yohei Hisada: How Well Do Mouse Leukemia Models Reflect Human Disease?
-
Nov 20, 2026, 13:20Ilenia Calcaterra: The Inferior Thyroid Arteries as a Window Into Cardiovascular Risk
-
Nov 20, 2026, 13:03Does Being Fit Protect Against VTE? – RPTH Journal